Michael Monovoukas runs AcuityMD, a Boston software company that sells commercial intelligence to the medical device industry, which is a category-of-one description that only becomes interesting when you learn what medtech commercial teams were doing before. They were, mostly, using Salesforce and spreadsheets to keep track of surgeons the way a college friend might keep track of birthdays. This turned out to be a $163 million business opportunity.
AcuityMD closed an $80 million Series C in April 2026, led by StepStone Group, with Benchmark, Redpoint Ventures, ICONIQ and Atreides Management stacked in behind. The round put the company at a reported $955 million valuation, which is the sort of number that would have amused Monovoukas in 2015, when he was shutting down his first startup, an optical pen called the WoundStylus that he built with his brother Demetri to measure the perimeter and area of wounds. That company, Monolysis Medical, lasted about a year. Monovoukas says it taught him how to sell to clinicians, which is a polite way of saying it taught him that clinicians do not answer their phones.
The AcuityMD pitch is that a field rep for, say, a spine device manufacturer has roughly the same job as a very well-informed matchmaker. They need to know which surgeon does which procedures, at which hospital, referred by which primary care doctor, using which competitor's implant, and whether that surgeon is likely to say yes to a lunch meeting on Thursday. This information exists. It exists in claims data, in referral networks, in procedure codes, in the loose weather of physician gossip. AcuityMD's product is essentially: stop making the rep assemble it in their head.
Monovoukas is a Princeton graduate with an MBA from Harvard Business School, which is the résumé the pattern-matching part of a venture investor's brain likes. But the operator résumé under it is more interesting. Before AcuityMD he worked at PatientPing, a Boston healthcare data company where he handled business development and finance and helped raise over $40 million, mostly in the un-glamorous work of negotiating channel partnerships with electronic medical record vendors. Before that, Bain. Before that, Princeton. The consulting-to-operator arc is common in Boston. The version of it that ends in a nearly billion-dollar SaaS company is less so.
The three co-founders are Monovoukas, Robert Coe as CTO (previously at Yext) and Lee Smith as head of commercial development (previously at Medtronic, which matters, because Medtronic sells the things AcuityMD's customers are trying to compete with). They founded the company in 2019 and moved patiently, or at least in a way that looked patient from outside: a $31 million Series A in 2022, a $45 million Series B in 2023, and the Series C in April of this year.
What Monovoukas has said about the Series C is that medtech AI does not work the way general-purpose AI works. "AI systems need deep workflow context tied directly to how MedTech organizations operate day to day," he told reporters at the time, which reads like a founder's line and is also, if you have ever watched a surgical rep try to use enterprise software between cases, plainly correct. AcuityMD is trying to be the shared intelligence layer under the field team - the thing the territory planner, the product launch lead and the rep in the parking lot of a Louisville hospital all look at.
He has been reasonably public about the fundraising philosophy that produced these outcomes. On the 20MinuteVC-adjacent podcast circuit he has talked about raising from a "position of strength" - the idea, roughly, that milestones and metrics compound faster than valuation multiples do, and that founders who chase the multiple end up trading it back at the next round. It is not an original observation. It is a well-executed one.
